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ical activity level, exacerbations, and school absences). The
impact of the following factors was investigated: family income
adequacy, parent education, parent employment, ethnicity,
parent immigration, language, parent marital status, and physi-
cal environment characteristics. The CPACG and Global Initia-
tive for Asthma (GINA) guideline deﬁnitions of asthma control
were compared. RESULTS: Only 11% of patients met the
requirements for acceptable control by satisfying all six para-
meters, while 20% satisﬁed ﬁve parameters, and 69% satisﬁed
four or fewer parameters. The multiple regressions indicated that
income adequacy had an impact on asthma control. Children
from families in the middle income adequacy quintile tended 
to have worse control. Higher numbers of asthma triggers,
increased physician or specialist visits, and daily use of anti-
inﬂammatories, were associated with lower levels of control. The
CPACG and GINA guidelines had a high level of agreement
(Weighted kappa = 0.74, p < 0.0001), although it was more dif-
ﬁcult to achieve acceptable asthma control in the CPACG guide-
lines. CONCLUSION: Despite the established effectiveness of
inhaled corticosteroids in the prevention of asthma exacerba-
tions, poor control remains a problem which was affected by
family income adequacy.
ARTHRITIS—Clinical Outcomes Studies
PAR1
MORTALITY RATE OF PATIENTS WITH RHEUMATOID
ARTHRITIS, PSORIASIS, CROHN’S DISEASE AND ULCERATIVE
COLITIS IN THE UNITED KINGDOM
Diels JK1, Bala M2, Budd D3
1Janssen Pharmaceutica, Beerse, Belgium, 2Johnson & Johnson,
Malvern, PA, USA, 3Johnson and Johnson Pharmaceutical Services,
Raritan, NJ, USA
OBJECTIVES: Rheumatoid arthritis (RA), psoriasis (PS),
Crohn’s disease (CD) and ulcerative colitis (UC) are autoimmune
related diseases. The purpose of this study was to estimate the
mortality rate of patients for each of these four conditions, rel-
ative to the overall population, adjusting for age and sex differ-
ences of the each patient group. METHODS: The analysis was
based on the THIN database for 2004. This data source is based
on the registration in GP-practices for a 4% representative
sample of the overall UK population. From the overall-popula-
tion sample (n = 2.278.100), patients were identiﬁed based on
the READ codes for each of these conditions in the previous 4
years. A subgroup of severe cases was identiﬁed, based on pre-
vious drug treatment. The standardised mortality ratio (SMR),
deﬁned as the proportion of the observed number of deaths and
the expected number, based on the age and gender speciﬁc 
mortality rates for the overall population, was calculated for
each patient group. 95% conﬁdence intervals were calculated.
RESULTS: 2% of the studied population suffers from one or
more of the four diseases: RA (0.44%), PS (1.3%), CD (0.14%)
or UC (0.16%). The SMR for all four disease conditions com-
bined was signiﬁcantly higher (132 [122,143]) compared to the
global UK population. Within the four groups, RA (158
[139,179]), CD (165 [108,241]) and PS (116 [103,130]) all
showed statistically increased mortality. The SMR was (ns)
higher for UC (122, [89,163]). Within each of these disease
groups, mortality was higher for severe patients, but did not
reach statistical signiﬁcance, possibly due to the relatively small
sample size of these subgroups. CONCLUSION: Patients suf-
fering from Crohn’s disease and rheumatoid arthritis have a 60%
increased mortality compared to the overall UK population.
Mortality is about 20% higher for patients with psoriasis and
ulcerative colitis.
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OBJECTIVES: To assess the health care utilization and associ-
ated costs for osteoarthritis (OA) patients, depending on the
primary drug prescribed for pain management. METHODS: A
claims database of privately insured patients (covering 31
employers, 1999–2004) was used to identify OA patients (ICD-
9-CM 715.XX) OA patients were categorized by primary pain
drug treatment—deﬁned as greatest days supply, 2003–2004—
for pain management (tramadol, acetaminophen w/codeine,
Cox-IIs, NSAIDS, short-acting opioids). A tramadol monother-
apy cohort was also constructed in which patients were pre-
scribed only tramadol for their pain (i.e., these patients did not
receive any of the other primary pain drugs listed above.) Mean
annual per patient health care costs were calculated for each drug
treatment cohort from a private payer’s perspective. RESULTS:
OA patients (n = 32,043) were often prescribed multiple drugs
simultaneously and/or sequentially to manage pain. Average
annual direct medical costs for OA patients were $8602 (ranging
from $6011 to $13,964 depending on the drug treatment
cohort). Average annual drug costs for OA patients were $2941
(ranging from $2108 to $8498 depending on the drug treatment
cohort). The tramadol monotherapy cohort had lower costs than
other cohorts. Cohort cost differences reﬂect, in part, more
severe comorbidity proﬁle and complex temporal treatment pat-
terns. CONCLUSION: Average annual direct costs of OA
patients were $11,543, which varies by drug treatment cohort.
OA patients use multiple simultaneously and/or sequentially to
treat their pain. Prescribing tramadol earlier to treat OA may
reduce therapy switching and associated costs and a once-a-day
version of tramadol may offer additional convenience, tolerabil-
ity and sleep improvement beneﬁts for OA patients. Future
research is needed to identify the temporal patterns of tramadol
use and associated outcomes.
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OBJECTIVES: To estimate incremental cost-utility ratios for
lumiracoxib relative to celecoxib for treating osteoarthritis (OA)
in Canada. Secondary comparators including six common treat-
ment algorithms (non-steroidal anti-inﬂammatory drugs with
and without proton pump inhibitors) were also evaluated.
METHODS: An existing Markov model with 3 month cycle
lengths and 5 year time horizon was adapted for Canada. Analy-
ses were performed from the third-party perspective of the
Ontario Ministry of Health. Treatments were assumed to be
equally efﬁcacious in treating symptoms of OA. Data on differ-
ences in rates of gastrointestinal (GI) and other (renal, skin,
hepatic) adverse events were obtained from published random-
ized trials. Quality-adjusted life years (QALYs) were calculated
separately for subgroups deﬁned a priori for age, sex, aspirin use,
and history of GI bleed. Common treatment pathways were
elicited from clinical experts. Costs of hospitalizations, labora-
tory tests, professional fees, and medications were obtained from
